Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Norovirus vaccine

Inactive Publication Date: 2018-08-30
RESILIENCE GOVERNMENT SERVICES INC
View PDF3 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0011]The present invention further provides methods of immunization against norovirus infections which comprises at least one immunization via a parenteral and/or a mucosal route. In some embodiments, one or more immunizations via a mucosal route is followed by one or more immunizations via a parenteral route or vice versa, to maximize both mucosal and systemic immune responses and protection against norovirus infection. In some embodiments, a dry powder vac

Problems solved by technology

Norovirus is also stable ex vivo which makes decontamination after an outbreak laborious and time consuming.
This disease burden strongly indicates the need for an effective vaccine; however, currently there is no FDA-approved norovirus

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Norovirus vaccine
  • Norovirus vaccine
  • Norovirus vaccine

Examples

Experimental program
Comparison scheme
Effect test

example 1

GI and GII Vaccine Formulation

[0051]Recombinant norovirus GI and GII VLPs expressed in Nicotiana benthamiana were obtained from Kentucky Bioprocessing (Owensboro, Ky.) as previously described [23] and used for powder formulations. Alternatively, recombinant Norovirus GI and GII VLPs expressed and purified from Sf9 insect cells using the baculovirus expression system were also used [18, 19].

[0052]The GelVac™ vaccine powders were made with a lyophilization-milling method. Liquid formulations were first prepared using a formulation that is comprised of the recombinant VLP in a solution with GelSite® polymer, povidone and lactose. They were then lyophilized. Following lyophilization, dried formulation contain 0.25% (w / w) GelSite®, 99% lactose and 0.05% povidone and 0 μg to 100 μg (based on ELISA data) of VLP per 20 mg of formulation, depending on the desired dose. The GI and GII VLPs were added together to the formulation to produce the multivalent powder or individually to produce the ...

example 2

Characterization of Vaccine Formulations

VLP Characterization

[0053]GI and GII VLP stocks were analyzed for the presence of intact VLPs by transmission electron microscopy prior to powder manufacturing. The results confirmed the presence of intact VLPs of the expected sizes (38 nm) for both GI and GII VLP stocks (FIG. 1).

[0054]VLP stability was established by determining the melt temperature of norovirus VLPs with SYPRO Orange. Briefly, SYPRO Orange (Sigma-Aldrich, St. Louis, Mo.) was diluted in PBS to make a final 4× concentration of SYPRO Orange. Each VLP was diluted in 4×SYPRO Orange to a final concentration of 1 mg / mL. Each sample was then placed in a fluorescent thermocycler and was run through a 25′C-95′C gradient while reading the fluorescent signal. The derivative of the signal was determined by taking the difference between successive points in the fluorescent signal. The noise was reduced by using a 4-point moving average filter. Melt curve plots are shown for GI (FIG. 2A) a...

example 3

Immunogenicity of Vaccine Formulations

Immunogenicity of GelVac™ GI and GII Powders

[0060]The immunogenicity of a GelVac™ vaccine powder formulated with GI VLP has been reported previously [20]. To further these studies, antigen dose-dependent immune responses were investigated with GelVac™ vaccine powders with GI or GII VLPs in female (250 g) Hartley guinea pigs. Animals were dosed with varying amounts of norovirus GI or GII VLPs (Table 3) or with a multivalent GI / GII VLP vaccine (50 μg each of GI and GII VLP, twice on days 0 and 21.

TABLE 3Monovalent Vaccine Animal Experimental DesignMonovalent Guinea Pig StudiesGroup #nTotal Antigen per Vaccination (μg)*1410024503415445541640.1740*Animals were immunized with a total of 20 mg of powder via both nares. Each nare received 10 mg of powder or half of the total antigen dose.

[0061]The vaccine powders were administered intranasally using Aptar Unit Dose Spray (UDS) Devices (Aptar Pharma, Congers, N.Y.), one per nare with half of the total a...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Fractionaaaaaaaaaa
Massaaaaaaaaaa
Massaaaaaaaaaa
Login to View More

Abstract

A dry powder norovirus vaccine is provided, which comprises at least two norovirus antigens representing different genogroups. The vaccine may be produced by formulation with a mixture of different antigens or combination of monovalent powders with each containing one antigen. The formulated vaccine is suitable for mucosal administration and soluble in aqueous solutions for parenteral administration. A method of immunization is also provided, which comprises at least one administration of the vaccine via mucosal and/or parental route. The immunization may have multiple administrations of the vaccine, i.e., one or more immunizations via a mucosal route followed by one or more immunizations via a parenteral route or vice versa, to maximize both mucosal and systemic immune responses and protection against norovirus infections.

Description

CROSS REFERENCE TO RELATED APPLICATIONS[0001]This application claims priority to U.S. Provisional Patent Application 62 / 211,289, filed Aug. 28, 2015, the entire disclosure of which is incorporated by reference herein.FIELD OF INVENTION[0002]The present invention is generally related to vaccines for prevention of infectious diseases and more specifically a vaccine for prevention and / or alleviation of norovirus infections and norovirus-related diseases and symptoms.BACKGROUND[0003]Norovirus, a single-stranded RNA virus in the Caliciviridae family, is the primary cause of nonbacterial gastroenteritis worldwide, accounting for 96% of all cases of viral gastroenteritis [1]. It is estimated, on average, that norovirus is responsible for 19 to 21 million infections per year [2] and up to 200,000 deaths in children under 5 years of age in developing countries [3, 4]. Norovirus is transmitted primarily through the fecal-to-oral route [5] making norovirus particularly threatening to individua...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K39/12A61K9/00A61K9/19A61K9/16
CPCA61K39/12A61K9/0095A61K9/19A61K9/1694A61K2039/5258A61K2039/55583A61K2039/541A61K2039/70C12N2770/16034C12N2770/16023C12N2770/16071A61K39/00A61K39/295A61P31/14
Inventor COBB, RONSPRINGER, MICHAELNI, YAWEI
Owner RESILIENCE GOVERNMENT SERVICES INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com